<h4>Background</h4>The present study aimed to investigate the effects of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on insulin resistance and weight reduction through advanced glycation end-product modulation in patients newly diagnosed with type 2 diabetes mellitus.<h4>Methods</h4>This study was designed as a 12-week, randomized, controlled, parallel trial. This evidence concerns the gene DPP4 and diabetes mellitus.